新型抗抑郁药维喹啉的药代动力学和生物利用度

Pharmacokinetics and bioavailability of viqualine, a new antidepressant.

作者信息

Fourtillan J B, Bouquet S, Girault J, Lefebvre M A, Maulet C, Courtois P

出版信息

Eur J Drug Metab Pharmacokinet. 1985 Jan-Mar;10(1):3-10. doi: 10.1007/BF03189690.

Abstract

A high performance liquid chromatographic assay was developed for plasma and urine levels measurement of viqualine. The assay was used to study the disposition of 25 mg intravenous and oral single doses in five healthy subjects. Two exponential terms were required to describe the disposition of the drug after intravenous and oral administration. The bioavailability of oral viqualine averaged 80%. The mean apparent half-life was 12.1 +/- 1.9 and 11.9 +/- 1.4 h (mean +/- s.e.m., n = 5) after 25 mg I.V. and oral dose respectively. The apparent volume of distribution (Vdss) were 1578 +/- 132 1 (after I.V. administration) and 1572 +/- 201 1 (after oral administration). The body and renal clearances were respectively 1.56 +/- 0.31 1.h-1. kg-1 and 1.57 +/- 0.31 1.h-1. kg-1, after 25 mg bolus I.V.

摘要

开发了一种用于测定血浆和尿液中维喹啉水平的高效液相色谱分析法。该分析法用于研究五名健康受试者静脉注射和口服25毫克单剂量后的药物处置情况。静脉注射和口服给药后，需要两个指数项来描述药物的处置情况。口服维喹啉的生物利用度平均为80%。25毫克静脉注射和口服给药后，平均表观半衰期分别为12.1±1.9小时和11.9±1.4小时（平均值±标准误，n = 5）。表观分布容积（Vdss）分别为1578±132升（静脉注射后）和1572±201升（口服后）。25毫克静脉推注后，机体清除率和肾清除率分别为1.56±0.31升·小时⁻¹·千克⁻¹和1.57±0.31升·小时⁻¹·千克⁻¹。